Obeticholic Acid CAS 459789-99-2

Khoom Piav Qhia ：

Khoom npe: Obeticholic Acid CAS TSIS: 459789-99-2

Txhais:

(3α, 5β, 6α, 7α) -6-Ethyl-3,7-dihydroxycholan-24-oic Acid;

3α, 7β-Dihydroxy-6α-ethyl-5β-cholan-24-oic Acid;

Tshuaj& Cov Khoom Uas Lub Cev:

Zog: Dawb kom dawb-cov hmoov dawb crystalline

Ntsuas: ≥99.0%

Qhov ceev: 1.091g / cm³

Melting point: ＞ 98 ℃

Lub Ntsiab Kub: 562.9 ℃ ntawm 760 mmHg

Flash Point: 308.3 ℃

Qhov Taw Qhia Refractive: 1.529

Vapor Siab: 0mmHg ntawm 25 ° C

PSA: 77.7600

LogP: 5.1140

Kev Tshaj Tawm: Dioxane (Sparingly), DMSO (Me ntsis), Methanol (Me ntsis);

Pawg: Cov Qauv; Steroids; Enzyme Activators thiab Inhibitors; Tshuaj / API Tshuaj Tsis Txaus / Cov Metabolites;

Cov Ntaub Ntawv Kev Nyab Xeeb:

HS Code: 2918990090

Cia:Muab cia rau hauv qhov chaw txias thiab qhuav zoo kaw lub thawv. Txav deb ntawm noo noo thiab muaj zog lub teeb / cua sov.

Daim ntawv thov:

1. 6α-ethyl-chenodeoxycholic acid tau paub lub npe hu ua INT-747. Nws tab tom muaj kev txhim kho raws li tus kws tshaj lij tshuaj kho mob rau ntau daim siab mob siab thiab cuam tshuam;

2. Cholan-24-oic acid, 6-ethyl-3,7-dihydroxy-, (3α, 5β, 6α, 7α, 8ξ) -, yog ib qho kev sib txuas ntawm bile acid Chenodeoxycholic Acid.

Peb lub Hoobkas tsim khoom Obeticholic Acid CAS 459789-99-2, cov thev naus laus zis ntau lawm, cov khoom lag luam ruaj khov, ua haujlwm zoo.

Cov Ntaub Ntawv Nres: Muaj Hauv Tshuag.

Peb tuaj yeem muab 6-Ethylchenodeoxycholic aicd daim ntawv pov thawj ntawm kev txheeb xyuas (COA), CAS 459789-99-2 Txoj Kev Ntsuam Xyuas (MOA), 3A, 7A -DIHYDROXY-6A -ETHYL-5B-CHOLAN-24-OIC ACID Cov Kev Ntsuas ntawm Cov Hluav Taws Xob (ROS ), (3alpha, 5beta, 6alpha, 7alpha) -6-Ethyl-3,7-dihydroxycholan-24-oic acid Cov Khoom Siv Kev Nyab Xeeb Cov ntaub ntawv (MSDS) thiab lwm yam kev txhawb nqa rau koj!

Obeticholic acid tau tsim los ntawm Kev Lag Luam Cov Tshuaj Lag Luam ntawm Tebchaws Meskas. Nws lub tebchaw patent tau thov rau Tebchaws Meskas thaum xyoo 2001, thiab tus lej patent yog US7138390. Tam sim no, tsis muaj qhov sib txuam patent tau thov rau hauv Suav teb. Obeticholic acid yog thawj cov tshuaj tsim rau kev kho mob siab mob siab hauv 20 xyoo, rau cov neeg mob uas tsis teb lossis tsis tuaj yeem tiv thaiv ursodeoxycholic acid.

Pharmacological effects: PBC yog ib qho mob cholestasis tshwm sim los ntawm dysplasia ntawm cov kua tsib lub plab lossis cov kua tsib cov kua tsib. Nws yaj tawm cov lipids hauv lub cell membrane, hloov permeability, thiab ntws tawm ntawm cov ntsiab lus ntawm tes, thiab thaum kawg hloov mus rau ib qho kab mob ntawm daim siab ua mob rau daim siab thiab mob ntsws. Tam sim no, cov tshuaj kho mob tseem ceeb rau kev kho mob ntawm PBC yog ursodeoxycholic acid, uas feem ntau ua rau hepatobiliary secretion los ntawm intracellular signaling molecule mitogen-activated protein kinase (MAPK) txoj hauv kev thiab tiv thaiv epithelial hlwb los ntawm kev puas tsuaj ntawm cov kua tsib kua qaub.

Obeticholic Acid (Obeticholic Acid), tseem hu ua 6-ethylchenodeoxycholic acid, yog ib qho tshiab ntawm chenodeoxycholic acid (CDCA) hauv tib neeg cov kua tsib kua qaub. Nws yog farnesoid derivative X receptor (FXR). ) Ntawm ntuj ligands. Obeticholic acid yog farnesoid X receptor agonist, uas tsis ncaj qha txwv cov gene ntawm cytochrome 7A1 (CYP7A1) los ntawm kev ua kom lub farnesoid X receptor. Vim tias CYP7A1 yog qhov kev txwv kev mob siab npaum li cas ntawm bile acid biosynthesis, obeticholic acid tuaj yeem kho cov kua tsib cov kua qaub ua kom muaj zog thiab siv los kho cov kev mob siab rau thawj lub cev thiab cov kab mob rog tsis muaj cawv. Obeticholic acid tau ua tiav tau zoo los ntawm Kev Tshuaj Yuam Tsaj Tshuaj hauv Tebchaws Meskas. Nws yog thawj cov tshuaj tsim los kho mob cholestatic mob siab hauv 20 xyoo. Txoj kev tshawb no yog rau cov neeg mob uas tsis teb tsis txaus lossis tsis tuaj yeem tiv taus cov qub qauv tshuaj kho mob ursodeoxycholic acid. Hauv cov tshuaj placebo tswj theem III, kev soj ntsuam obeticholic acid (OCA) tau nce theem ntawm ob lub tshuab biomarkers cuam tshuam nrog txo kev pheej hmoo ntawm daim siab hloov chaw. Cov ntsiab lus kawg ntawm kev tshawb fawb hauv kev soj ntsuam yog tias alkaline phosphatase raug txo tsawg kawg 15%, qhov kev ua ntawm cov ntshiab alkaline phosphatase qis dua li 1,67 npaug ntawm qhov txwv qis ntawm ib txwm, thiab bilirubin yog nyob rau hauv thaj chaw ib txwm, alkaline phosphatase yog siv los qhia mob siab daim siab Tus neeg nqus ntshav txog qib kawm.

Obeticholic acid tseem tab tom sim tshuaj los kho ib qho ntau dua ntawm cov rog rog tsis rog cawv tsis yog cawv cawv. Theem 2 kev soj ntsuam kawm ntawm cov tshuaj no rau kev kho mob ntawm qhov ntsuas tau raug tso tseg ntxov vim nws txoj kev ua tau zoo. EvaluatePharma kwv yees hais tias kev muag cov kua qaub obeticholic hauv xyoo 2020 tuaj txog yuav muaj txog 2,992 billion dollars Asmeskas. Obeticholic acid ntsig txog cov lej ua patent hauv Suav: CN200980154713 thiab CN200880006937. Kev mob siab ua kom tsis rog rau lub siab (NAFLD) yog ib qho kev mob tshwm sim ntawm kev mob plab hauv lub siab, feem ntau cuam tshuam nrog kev rog, dyslipidemia thiab insulin tsis kam. Feem ntau hais lus, NAFLD tuaj yeem muab faib ua ob qhov subtypes: yooj yim rog rog thiab tsis muaj cawv cawv (NASH). Cov rog ua kom yooj yim yog qhov tsis muaj kev nce qib, thaum NASH tuaj yeem hloov mus rau qog ntshav thiab txawm tias daim siab ua haujlwm. mob cancer.

Cov kev tshawb fawb pom tias insulin tsis kam ua lub luag haujlwm tseem ceeb hauv pathogenesis ntawm NAFLD / NASH. Cov tshuaj tua kab mob insulin xws li thiazolidinedione tshuaj tau ua pov thawj ua rau muaj txiaj ntsig zoo hauv kev txhim kho daim siab mob siab thiab cov ntsiab lus rog, tab sis lawv tsis tuaj yeem thaiv qhov mob ntawm fibrosis tshwm sim los ntawm NASH. Farnesoid derivatives X receptors tseem muaj cov txiaj ntsig ntawm kev txhim kho cov tshuaj tiv thaiv insulin thiab ua lub luag haujlwm tseem ceeb hauv cov metabolism ntawm cov kua tsib cov kua qaub, lipids thiab suab thaj.

Obeticholic acid yog tib neeg cov kua tsib acid mimic. Nws yog ib qho chenodeoxycholic acid ua ib-hluavtaws thiab ib tus agonist ntawm farnesoid derivative X receptors. Nws tau tsim los ntawm Kev Txhim Kho Cov Khoom Siv rau kev kho mob hauv thawj lub siab ua haujlwm hauv kev kho mob ntawm PBC, ntshav tsis yog cawv thiab lwm yam kab mob siab thiab mob hnyuv, cov tsiaj sim tau ua pov thawj nws cov ntxim rau kev txhim kho insulin tsis kam thiab txo cov rog rog. 6 lub lis piam multicenter, sib koom, ob lub qhov muag tsis pom kev soj ntsuam los ntawm Tebchaws Meskas suav nrog 64 cov neeg mob ntshav qab zib hom 2 thiab NAFLD, uas ua pov thawj tias obeticholic acid tuaj yeem txhim kho daim siab mob siab thiab mob siab ua rau lub siab ntxiv rau insulin rhiab heev. Qib qib Fibrosis, thiab muaj qee yam ntxim li yuav txo lub cev nqaij daim tawv. Txawm li cas los xij, cov lus xaus no tseem xav tau kev ua raws qib ntev dua, thiab nws yuav tsum muaj kev paub tseeb los ntawm daim siab mob siab.

Yog tias koj txaus siab rau peb cov khoom lossis muaj lus nug, thov koj xav tiv tauj peb!

Cov khoom lag luam hauv qab patent yog muab rau R& D lub hom phiaj nkaus xwb. Txawm li cas los xij, lub luag haujlwm kawg tau txiav txim siab nrog cov neeg yuav khoom.

Cim npe nrov: obeticholic acid cas 459789-99-2, tuam ntxhab, lwm tus neeg, Hoobkas, yuav, hauv Tshuag

• Tug: Tsis muaj
• Tom ntej: Sitagliptin Phosphate Monohydrate CAS 654671-77-9